netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for Cetuximab found 22 matches

   


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (08.01.05)
link in drug section NICE TA145: Head and neck cancer - cetuximab (08.01.05)
link in drug section NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
link in drug section NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
link in drug section NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
link in drug section NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (08.01.05)
link in drug section NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (08.01.05)
link in drug section NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (08.01.05)
link in drug section NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (08.01.05)
link in drug section TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.03)
link in drug section TA 176: Cetuximab for the first-line treatment of metastatic colorectal cancer (08.01.05)
link in drug section TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (08.01.03)


 
netFormulary